Albumin-Binding Polypeptides for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as lipodystrophy, dyslipidemia, and diabetes lack polypeptides with extended half-lives and convenient dosing regimens, leading to suboptimal therapeutic outcomes.
Innovation Solution
Engineered polypeptides are developed that incorporate an albumin binding domain (ABD) combined with a biologically active hormone domain (HD), such as leptin, to enhance binding affinity for albumin, thereby increasing the duration of action and reducing renal clearance and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional polypeptides are used for treating metabolic diseases, then therapeutic efficacy is achieved, but duration of action is short and dosing frequency must be high
Solution Approach 1:
The invention introduces albumin as an intermediary carrier protein that binds to the therapeutic polypeptide. This albumin-polypeptide complex extends the circulation half-life of the therapeutic agent by utilizing albumin's long residence time in plasma, thereby reducing dosing frequency while maintaining therapeutic efficacy
Solution Approach 2:
The invention creates a composite therapeutic structure by fusing the active polypeptide with an albumin-binding domain (ABD). This composite molecule combines the therapeutic function of the original polypeptide with the extended circulation properties of albumin, achieving both sustained duration of action and reduced dosing frequency
2Reliability
If polypeptides are administered frequently to maintain therapeutic levels, then therapeutic efficacy is maintained, but patient compliance and convenience deteriorate
Solution Approach 1:
Albumin serves as a mediator that prolongs the circulation time of the therapeutic polypeptide. By binding to albumin, the polypeptide maintains therapeutic levels for extended periods, enabling less frequent dosing and thereby improving patient compliance without compromising therapeutic efficacy
3Duration of action of stationary object
If polypeptides are cleared rapidly by renal filtration, then half-life is short, but therapeutic coverage is insufficient
Solution Approach 1:
The invention employs albumin as a protective intermediary that shields the therapeutic polypeptide from rapid renal clearance. The albumin-polypeptide complex is too large for efficient glomerular filtration, thereby extending the half-life and ensuring adequate therapeutic coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered polypeptides demonstrate extended duration of action, reduced immunogenicity, and maintained therapeutic efficacy, providing effective treatment for metabolic disorders with improved dosing regimens.
Implementation Method 1
engineered polypeptides which incorporate an albumin binding domain in combination with a biologically active peptide... because the engineered polypeptides described herein can bind albumin, the compounds can be sequestered (e.g., bound to albumin) while in the circulation
Data Source
Figure 1A
Figure 1A
Figure 1A
AI summary
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.